We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ATXN7-Related Cone-Rod Dystrophy: The Integrated Functional Evaluation of the Cerebellum (CERMOI) Study.
- Authors
Nassisi, Marco; Coarelli, Giulia; Blanchard, Benoit; Dubec-Fleury, Charlotte; Drine, Karima; Kitic, Nicolas; Sancho, Serge; Hilab, Rania; Tezenas du Montcel, Sophie; Junge, Candice; Lane, Roger; Arnold, H. Moore; Durr, Alexandra; Audo, Isabelle
- Abstract
Key Points: Question: What are the ophthalmic features of the spinocerebellar ataxia type 7 (SCA7) carriers with preataxia included in this study? Findings: A cross-sectional study of 15 SCA7 carriers revealed correlations between the number of CAG repeats and visual assessments in 9 carriers with preataxia, including visual acuity, retinal sensitivity, and outer nuclear layer thickness. For carriers with ataxia, cerebellar features progressed substantially together with ophthalmic abnormalities. Meaning: The correlations between SCA7 disease severity and ophthalmic manifestations found in this study emphasize the potential of visual assessments as biomarkers for disease progression and therapeutic evaluation. This study describes baseline ophthalmological biomarkers in spinocerebellar ataxia type 7 carriers included in the Integrated Functional Evaluation of the Cerebellum (CERMOI) cross-sectional study. Importance: Reliable biomarkers with diagnostic and prognostic values are needed for upcoming gene therapy trials for spinocerebellar ataxias. Objective: To identify ophthalmological biomarkers in a sample of spinocerebellar ataxia type 7 (SCA7) carriers. Design, Setting, and Participants: This article presents baseline data from a cross-sectional natural history study conducted in Paris, France, reference centers for rare diseases from May 2020 to April 2021. Data were analyzed from September to December 2022. Fifteen adult ATXN7 pathogenic expansion carriers (9 with preataxia and 6 with ataxia) were included, all with a Scale for the Assessment and Rating of Ataxia (SARA) score of 15 of 40 or lower. Patients were recruited at the Paris Brain Institute, and all contacted patients accepted to participate in the study. Main Outcomes and Measures: Three visits (baseline, 6 months, and 12 months) were planned, including neurological examination (SARA and Composite Cerebellar Functional Severity Score), ophthalmological examination (best-corrected visual acuity, microperimetry, full-field electroretinogram, optical coherence tomography, and fundus autofluorescence imaging), and neurofilament light chain (NfL) measurements. Here we report the baseline ophthalmic data from the cohort and determine whether there is a correlation between disease scores and ophthalmic results. Results: Among the 15 included SCA7 carriers (median [range] age, 38 [18-60] years; 8 women and 7 men), 12 displayed cone or cone-rod dystrophy, with the number of CAG repeats correlating with disease severity (ρ, 0.73, 95% CI, 0.34 to 0.90; P <.001). Two patients with cone-rod dystrophy exhibited higher repeat numbers and greater ataxia scores (median [range] SARA score, 9 [7-15]) compared to those with only cone dystrophy (median [range] SARA score, 2 [0-5]). A correlation emerged for outer nuclear layer thickness with SARA score (ρ, −0.88; 95% CI, −0.96 to −0.59; P <.001) and NfL levels (ρ, −0.87; 95% CI, −0.86 to 0.96; P <.001). Moreover, ataxia severity was correlated with visual acuity (ρ: 0.89; 95% CI, 0.68 to 0.96; P <.001) and retinal sensitivity (ρ, −0.88; 95% CI, −0.96 to 0.59; P <.001). Conclusions and Relevance: In this cross-sectional study, retinal abnormalities were found at preataxic stages of the disease. Most of the carriers presented with cone dystrophy and preserved rod function. The outer nuclear layer thickness correlated with SARA score and plasma NfL levels suggesting nuclear layer thickness to be a biomarker of disease severity. These findings contribute to understanding the dynamics of SCA7-related retinal dystrophy and may help lay the groundwork for future therapeutic intervention monitoring and clinical trials. Trial Registration: ClinicalTrials.gov Identifier: NCT04288128
- Publication
JAMA Ophthalmology, 2024, Vol 142, Issue 4, p301
- ISSN
2168-6165
- Publication type
Article
- DOI
10.1001/jamaophthalmol.2024.0001